Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $5.50
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have received a consensus rating of “Hold” from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year […]
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have received a consensus rating of “Hold” from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year […]
